HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

BMY 21190

structure given in first source

Also Known As:

BMY-21190; BMY21190

Networked: 2 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Imidazoles: 150
      - BMY 21190: 2
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 146
      - BMY 21190: 2

Related Diseases

1.	Infarction (Infarctions) 01/01/1995 - "It is suggested that BMY21190 reduces infarct size through the inhibition of neutrophil infiltration in the canine model." 01/01/1995 - "The infarct zone/area at risk of the BMY21190 group was significantly smaller than that of the vehicle group (36.1 +/- 7.8%; 62.4 +/- 4.3%, respectively; p < 0.05). " 01/01/1995 - "This study was performed to assess the effect of BMY21190, an inhibitor of cAMP phosphodiesterase, on infarct size using a canine ischemic model that underwent a 90-min occlusion and a 6-hour reperfusion of the left coronary artery. " 01/01/1995 - "Effects of BMY21190, an inhibitor of cAMP phosphodiesterase, on infarct size and myeloperoxidase activity in the ischemic myocardium of a canine occlusion-reperfusion model."
2.	Thrombosis (Thrombus) 10/01/1993 - "BMY21190 treatment reduced the development of the LCX thrombus mass, as compared to that in the controls. " 10/01/1993 - "BMY21190 was evaluated for its ability to modify the development of experimental thrombosis resulting from anodal current injury (100 microA for 6 h) of the intimal surface of the left circumflex coronary artery (LCX) in anesthetized dogs. " 10/01/1993 - "Antithrombotic effects of BMY21190, an inhibitor of cAMP phosphodiesterase, in a canine model of coronary artery thrombosis."

Related Drugs and Biologics

1.	3',5'-Cyclic-AMP Phosphodiesterases (3',5' Cyclic Nucleotide Phosphodiesterase)
2.	Peroxidase (Myeloperoxidase)